open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15
Get Citation

Occurrence of malignant lesions in patients referred to 131I therapy due to benign thyroid diseases

Maria H. Listewnik, Bożena Birkenfeld, Maria Chosia, Bogumiła Elbl, Barbara Zaborek

open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15

Abstract

Introduction: 131I therapy should be performed after exclusion of any morphological pathology that needs surgery - usually malignancy or its suspicion. The aim of the study was to evaluate the range of this problem in patients considered for radioiodine therapy due to benign thyroid diseases.
Material and methods: In 2000-2005 year 3663 patients with hyperthyreosis were referred to 131I therapy. All patients were subjected to routine procedure which comprised of thyroid function assesment, radioiodine uptake, thyroid scan, ultrasound examination. In 505 (13.8%) patients according to indications fine needle biopsy (FNAB) with cytological examination was performed. 131I therapy dose was given to 3083 (84.2%) patients.
Results: Eight patients (1.6%) were positive or with suspicion of malignancy on FNAB. All but one had no cytological examination before referral. The diameter of the lesions ranged from 6 to 28 mm. Cytological diagnosis was: in 3 patients - ca papillare, in 3 - follicular tumour, in 1 - Hürthle’a cell tumour, and in one patient histopathological examination was required without definitive cytological diagnosis. In six patients primary diagnosis was toxic nodular goiter, in three patients Graves’ disease.
Conclusion: 1. Obtained data underline the need for bigger malignancy alert of nuclear medicine physicians during qualification of patients for 131I treatment despite of patients preselection by referring doctors.
2. Performing FNAB is a very important part of qualification to radioiodine treatment.
3. Thyroid scan is supportive in choosing a proper place for FNAB.

Abstract

Introduction: 131I therapy should be performed after exclusion of any morphological pathology that needs surgery - usually malignancy or its suspicion. The aim of the study was to evaluate the range of this problem in patients considered for radioiodine therapy due to benign thyroid diseases.
Material and methods: In 2000-2005 year 3663 patients with hyperthyreosis were referred to 131I therapy. All patients were subjected to routine procedure which comprised of thyroid function assesment, radioiodine uptake, thyroid scan, ultrasound examination. In 505 (13.8%) patients according to indications fine needle biopsy (FNAB) with cytological examination was performed. 131I therapy dose was given to 3083 (84.2%) patients.
Results: Eight patients (1.6%) were positive or with suspicion of malignancy on FNAB. All but one had no cytological examination before referral. The diameter of the lesions ranged from 6 to 28 mm. Cytological diagnosis was: in 3 patients - ca papillare, in 3 - follicular tumour, in 1 - Hürthle’a cell tumour, and in one patient histopathological examination was required without definitive cytological diagnosis. In six patients primary diagnosis was toxic nodular goiter, in three patients Graves’ disease.
Conclusion: 1. Obtained data underline the need for bigger malignancy alert of nuclear medicine physicians during qualification of patients for 131I treatment despite of patients preselection by referring doctors.
2. Performing FNAB is a very important part of qualification to radioiodine treatment.
3. Thyroid scan is supportive in choosing a proper place for FNAB.
Get Citation

Keywords

hyperthyroidism; thyroid neoplasm; Graves’ disease; goiter nodular; 131I

About this article
Title

Occurrence of malignant lesions in patients referred to 131I therapy due to benign thyroid diseases

Journal

Endokrynologia Polska

Issue

Vol 57, Supp. A (2006)

Pages

2-6

Published online

2006-09-25

Keywords

hyperthyroidism
thyroid neoplasm
Graves’ disease
goiter nodular
131I

Authors

Maria H. Listewnik
Bożena Birkenfeld
Maria Chosia
Bogumiła Elbl
Barbara Zaborek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl